提高系统性红斑狼疮临床研究中的祖先多样性
非白人人群更易患系统性红斑狼疮(SLE),但在SLE临床试验中代表性不足,药物疗效与安全性可能受祖先背景影响。会议从历史、社会、经验和实用角度评估了非白人SLE患者参与临床研究减少的问题,并讨论了几项增加非白人患者参与SLE和非SLE研究的干预项目,强调需要在社会、机构、研究团队、转诊医生和患者教育层面进行变革以实现SLE临床研究中公平的祖先代表性。
要点
- 非白人人群SLE发病率更高但临床试验代表性不足,药物疗效安全性可能受祖先背景影响。
- 会议从历史、社会、经验和实用角度评估非白人SLE患者参与临床研究减少的问题。
- 需在社会、机构、研究团队、转诊医生和患者教育层面变革以实现公平祖先代表性。
核心结论
- 为实现SLE临床研究中公平的祖先代表性,需要在社会、机构、研究团队、转诊医生和患者教育层面进行变革。
主要发现
- 非白人人群更易患SLE但在SLE临床试验中代表性不足,药物疗效和安全性可能受祖先背景影响。
- 非白人人群进入临床试验的障碍被放大。
- 会议从历史、社会、经验和实用角度评估了非白人SLE患者参与临床研究减少的问题。
- 会议描述并讨论了几项增加非白人患者参与SLE和非SLE研究的干预项目。
临床怎么用
- 临床研究中需关注非白人SLE患者的招募与保留,并在社会、机构、研究团队、转诊医生和患者教育层面采取干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-White people are more likely to develop systemic lupus erythematosus (SLE) yet are underrepresented in SLE clinical trials. The efficacy and safety of drugs may be influenced by ancestry, and ancestrally diverse study populations are necessary to optimize treatments across the full spectrum of patients. However, barriers to entry into clinical trials are amplified in non-White populations. To address these issues, a conference was held in Bethesda, Maryland, from October 15-16, 2019, entitled "Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies: Overcoming the Barriers." Conference participants included people with lupus, lupus physicians, lupus clinical trialists, treatment developers from biotechnology, social scientists, patient advocacy groups, and US government representatives (The Office of Minority Health, Centers for Disease Control and Prevention, National Institutes of Health, and the Food and Drug Administration). For all these groups, the organizers of the conference purposefully included people of non-White ancestry. Decreased participation of non-White SLE patients in clinical research was evaluated through historical, societal, experiential, and pragmatic perspectives, and several interventional programs to increase non-White patient participation in SLE and non-SLE research were described and discussed. The presentations and discussions highlighted the need for changes at the societal, institutional, research team, referring physician, and patient education levels to achieve equitable ancestral representation in SLE clinical studies.
引用
- Williams JN, Dall'Era M, Lim SS, et al. Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. Arthritis Care Res (Hoboken). 2022. PMID: 33026693. doi:10.1002/acr.24474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。